Answers are grounded in this paper and cite their sources.
Retrospective cohort study reveals superior overall survival with ibrutinib versus stem cell transplant in relapsed del(17p) chronic lymphocytic leukaemia, indicating targeted therapy benefits.
After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23-0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort. Our large, retrospective analysis suggests that ibrutinib treatment may offer improved overall survival and progression-free survival compared to alloHSCT in patients with relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.
No takes yet. Share an insight, caveat, or question.
Awan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: